Xilio Therapeutics, Inc.
XLOHealthcare|Biotechnology|US
$8.62
+0.12 (+1.41%)
DCF Value
$329.92
Tangible Book / Share
$3.72
Cash / Share
$7.01
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05684965 XTX301 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | P1P2 | Recruiting | 358 | Open-label | XTX301 |
| NCT07688577 XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors | Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced Solid Tumor | P1P2 | Recruiting | 180 | Open-label | XTX501 |
| NCT07765836 Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC | Pancreatic Cancer Metastatic | P2 | Not Yet Recruiting | 40 | Open-label | vilastobart (XTX101), Retifanlimab |
| NCT04896697 Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors | Advanced Solid Tumor | P1P2 | Completed | 125 | Open-label | vilastobart (XTX101), Atezolizumab, vilastobart (XTX101) |
| NCT05052268 XTX202 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | P1P2 | Completed | 95 | Open-label | XTX202 |